



09 November 2021

EudraCT Number: 2018-000648-25

Sponsor Name: BioMarin Pharmaceutical Inc.

Sponsor Protocol Number: 165-502 (OPTIC Study)

Study Title: A Phase 3b, Open-Label, Single Arm, Multi-Centre Study to Assess the Safety and Efficacy of Pegvaliase (BMN 165) Treatment in adults With Phenylketonuria Not Controlled with Current Management

The study referenced above was terminated prior to any patients being consented or recruited. No study report was produced.

Sincerely,

DocuSigned by:

8039D3228EE7443...

Andrew Hart
Director
Global Medical Affairs, Evidence Generation